Cambridge Tech and Life Sciences Firms Raise Nearly $2.5 Billion in 12 Months

By Daniel Okafor

Cambridge technology and life sciences companies raised almost $2.5 billion between 1 November 2025 and 29 October 2026, according to Business Weekly's deal tracking. Technology firms pulled in $1.25 billion across 16 disclosed rounds. Life sciences matched the pace with $1.23 billion over 25 disclosed deals.

The momentum is accelerating, not fading. Funding from 1 January to 29 October 2026 hit $2.273 billion, up 33.77% from the $1.69 billion raised in the same period of 2025.

Four companies drove the haul: defence company Cambridge Aerospace ($500 million across two tranches), generative materials platform CuspAI ($450 million), surgical robotics pioneer CMR Surgical ($400 million), and oncology drug developer CellCentric ($220 million).

How did Cambridge Aerospace reach a $3.4bn valuation?

Cambridge Aerospace closed a $300 million Series C in August, led by DFJ Growth and backed by Lux, Accel, Lakestar, Never Lift, Ora Global and Elad Gil & Co. The round valued the firm at $3.4 billion. It arrived four months after a $200 million Series B co-led by Elad Gil & Co and Spark Capital. The company is under two years old. Chief executive Professor Steven Barrett leads it, alongside chief commercial officer Chris Sylvan, a Royal Marines veteran, and serial founder Junaid Hussain.

CuspAI confirmed a $450 million Series B in July at a $2.6 billion valuation. Kleiner Perkins and NEA co-led the round, with Jeff Bezos's Bezos Expeditions joining. Backers also included Glade Brook Capital Partners, Lux Capital, AMD Ventures, Tru Arrow Partners, StepStone, Britain's Sovereign AI Venture Fund, Invest-NL and John Doerr. Follow-on capital came from Temasek, Basis Set Ventures, Giant Ventures, Touring Capital, Prosus, Phoenix Court and Northzone. Co-founder and CEO Dr Chad Edwards runs the company from Cambridge; co-founder and CTO Professor Max Welling operates from Amsterdam. CuspAI has since expanded into Berlin, Tokyo, Singapore and the United States.

Quantum firms scored two notable wins. Quantinuum, which completed a 2026 US public listing, secured a $100 million White House CHIPS R&D award to scale trapped-ion quantum hardware manufacturing in the US. It stands as the only company with that architecture to win federal funding. Nu Quantum secured an oversubscribed $60 million Series A in December, led by National Grid Partners, with Gresham House Ventures and Morpheus Ventures joining alongside Amadeus Capital Partners, IQ Capital, Ahren Capital, Cambridge Enterprise Ventures, East Innovate, NSSIF and Sumitomo's Presidio Ventures.

Battery-maker Nyobolt reached a $1 billion valuation in May after a $60 million round led by NASDAQ-listed Symbotic, with Latitude, IQ Capital, CBMM and Scania Invest participating. Co-founder and CEO Dr Sai Shivareddy said: "The enterprises deploying autonomous systems at scale can't afford downtime, swap time, or power flickers. Our technology delivers a powerful trifecta: improved performance, exceptional durability and a more sustainable operation, enabling a new generation of machines to run harder and smarter."

Smaller tech deals filled out the table:

• Dogtooth Technologies: $18.7 million (£14m) in equity, Innovate UK grants and a Kineo Finance leasing facility to scale autonomous strawberry harvesters already working with Dyson Farming.
• Kigen, an Arm spin-out: $13.6 million (£10m) from Salica Investments to expand enterprise eSIM cybersecurity across IoT, M2M and satellite operations.
• Barocal: a $10 million May seed round for refrigerant-free heating and cooling, backed by World Fund, Breakthrough Energy Discovery, Cambridge Enterprise Ventures and IP Group.
• Worldmodeldata: $9.37 million (£7m) in July seed capital from Iona Star Capital, under founder Rhea Loucas and board chair Lord Richard Allan.
• Silicon Microgravity: $8 million (£6m) for MEMS accelerometers in defence and space; Theia Insights: $8 million Series A led by MiddleGame Ventures for its institutional asset-management platform.

Why did Stryker put $400m into CMR Surgical?

Michigan-based medical device giant Stryker committed $400 million to CMR Surgical earlier this month. The deal grants Stryker exclusive US commercial agency rights for CMR's Versius surgical robotics portfolio and an explicit option to acquire the company outright. CMR CEO Massimiliano Colella said: "Stryker's investment will give us additional strength to accelerate innovation and the continued global expansion of the Versius portfolio, while its scale and deep customer relationships create a significant growth opportunity in the United States."

CellCentric closed a heavily oversubscribed $220 million Series D in May and is preparing for a US public listing. Venrock Healthcare Capital Partners led the round, joined by Fidelity Management & Research Company, Sofinnova Partners, HBM Healthcare, Pfizer, RA Capital and Forbion. The capital funds registrational studies for inobrodib in multiple myeloma. CEO Will West said: "We've landed a really top tier syndicate to take inobrodib through to a registration to treat multiple myeloma. We got the green light from the FDA on 11 March for our chosen final dose, schedule, patient population. DOMMINO-1 is now fully underway and the full Phase III, DOMINO-2, starts in July/Aug. Over a third of a $billion raised in 12 months. It's all because of the data!" CellCentric won Business of the Year at the Business Weekly Awards in September.

What else closed in life sciences?

The rest of the cluster's deals spanned clinical-stage oncology to microbiome medicine:

• Artios Pharma: $115 million oversubscribed Series D in November 2025, co-led by SV Health Investors and RA Capital Management, advancing ATR inhibitor alnodesertib through FDA Fast Track trials in pancreatic and colorectal cancers.
• Immutrin: $86 million (£65m) Series A in March, led by Frazier Life Sciences, for proof-of-concept trials in ATTR cardiomyopathy. Founded by Professor Sir Mark Pepys, Nobel Laureate Sir Gregory Winter and Professor Daniel Christ. CEO Mihriban Tuna said: "Having been involved in building Immutrin from its earliest days, I'm delighted to welcome support from our new and existing investors in this strong global syndicate."
• STORM Therapeutics: $56 million Series C in April from M Ventures, Pfizer Ventures, Taiho Ventures, IP Group, UTokyo IPC and FTI, funding a Phase 2 study of METTL3 inhibitor STC-15 in sarcoma, with the first patient dosed.
• bit.bio: $50 million Series C led by M&G Investments. The 2016 Cambridge spin-out reprogrammes stem cells via opti-ox; its largest shipment to date was 1.6 billion cells.
• Microbiotica: $48 million first close this month, led by British Business Bank with Tencent, IP Group, Cambridge Innovation Capital, Flerie Invest and Seventure Partners, moving MB310 into Phase 2 in ulcerative colitis after positive COMPOSER-1 Phase 1b results.
• Mestag Therapeutics: $40 million in March from SV Health Investors, Johnson & Johnson Innovation, Forbion, GV and Northpond Ventures for its fibroblast-immunology antibody pipeline.
• Alchemab Therapeutics: $34 million (£25m) from British Business Bank in July — the bank's largest life sciences investment to date — after its first asset reached clinical trials via a Lilly licensing deal in under three years.
• T-Therapeutics: $32 million last December, lifting its Series A to $91 million, with Tencent and BGF joining existing backers Sofinnova Partners, F-Prime, Digitalis Ventures, Cambridge Innovation Capital, Sanofi Ventures and the University of Cambridge Venture Fund.

Further down the list sit Lightcast ($27m), Qureight ($20m), Undecimal Bio ($18m), TRIMTECH ($14m), Nuclera ($12m), Lucida Medical ($11.46m), KluraLabs ($10.85m), Ride Therapeutics (c$7.3m), Eco-Inject ($7.02m), PlaqueTec ($5m), 52North ($4.24m), Semarion ($3.8m), OutSee ($3.36m), Axol Bioscience ($2.8m) and auryx ($2m).

The pattern is clear. US strategic capital, exemplified by Stryker's option to acquire CMR outright, is now a structural feature of the cluster, and with 2026 funding already a third ahead of last year, Cambridge's mega-round pipeline shows no sign of thinning.